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ABSTRACT
Objectives To determine the feasibility of a large- scale 
deinitive multicentre trial of prehospital continuous 
positive airway pressure (CPAP) in acute respiratory failure.
Design A single- centre, open- label, individual patient 
randomised, controlled, external pilot trial.
Setting A single UK Ambulance Service, between August 
2017 and July 2018.
Participants Adults with respiratory distress and 
peripheral oxygen saturations below British Thoracic 
Society target levels despite controlled oxygen 
treatment.
Interventions Patients were randomised to prehospital 
CPAP (O- Two system) versus standard oxygen therapy in a 
1:1 ratio using simple randomisation.
Primary and secondary outcome measures Feasibility 
outcomes comprised recruitment rate, adherence to 
allocated treatment, retention and data completeness. The 
primary clinical outcome was 30- day mortality.
Results 77 patients were enrolled (target 120), including 
7 cases with a diagnosis where CPAP could be ineffective 
or harmful. CPAP was fully delivered in 74% (target 75%). 
There were no major protocol violations. Full data were 
available for all key outcomes (targets ≥90%). Overall 
30- day mortality was 27.3%. Of these deceased patients, 
14/21 (68%) either did not have a respiratory condition or 
had ceiling of treatment decisions implemented excluding 
hospital non- invasive ventilation and critical care.
Conclusions Recruitment rate was below target and 
feasibility was not demonstrated. Limited compliance 
with CPAP, and dificulty in identifying patients who 
could beneit from CPAP, indicate that prehospital 
CPAP is unlikely to materially reduce mortality. A 
deinitive effectiveness trial of CPAP is therefore not 
recommended.
Trial registration number ISRCTN12048261; Post-
results.
BACKGROUND
Acute respiratory failure (ARF) is a common 
medical emergency caused by cardiac or 
respiratory diseases, including heart failure, 
pneumonia, chronic obstructive pulmonary 
disease (COPD) and asthma.1 The inci-
dence of ARF has been estimated at 80 cases 
per 100 000 per year in the USA.1 Although 
varying according to the underlying cause, 
the overall risk of death is high, with estimates 
of 30- day mortality ranging between 12% and 
20%.2 ARF has substantial health services 
costs, with patients often requiring prolonged 
hospital stays, ventilatory support and critical 
care admissions.3 4 ARF is responsible for over 
3 million National Health Service (NHS) bed 
days and hospital costs of £9.6 million per 
year in England.5 6
Current prehospital management of ARF 
in the NHS uses a standard management 
approach of controlled oxygen therapy, 
Strengths and limitations of this study
 Ź This study provides important information regarding 
the feasibility of a large- scale deinitive randomised 
controlled trial investigating prehospital continuous 
positive airway pressure in acute respiratory failure.
 Ź Expert recommendations for pilot randomised con-
trolled trials were followed.
 Ź A pragmatic study design was used to maximise 
generalisability to real- life prehospital practice.
 Ź A novel allocation concealment method using identi-
cal sealed boxes was used.
 Ź Patients and clinicians were not blinded to the 
intervention.
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supplemented by specific ancillary treatments directed 
at the underlying disease.7 This therapy is usually deliv-
ered by ambulance service personnel without physician 
support. Continuous positive airways pressure (CPAP) is 
widely used in hospital to treat ARF due to COPD, pneu-
monia, decompensated obstructive sleep apnoea, cardio-
genic pulmonary oedema and chest wall trauma8; and it 
has been suggested that it may be more effective if deliv-
ered earlier, that is, en route to hospital.5 The difficulties 
of prehospital diagnosis mean that prehospital CPAP is 
likely to be applied generally to all cases of ARF, rather 
than directed towards those due to a specific cause.
Existing research investigating prehospital CPAP is 
inconclusive. A recent evidence synthesis suggested that 
prehospital CPAP may reduce the risk of mortality in ARF 
compared with standard treatment, but noted that the 
primary studies were relatively small, heterogeneous, at 
risk of bias, and were provided by specialist services, so 
may not be applicable to routine prehospital practice.5 
These findings suggest that although prehospital CPAP 
is a promising and potentially efficacious therapy, a large 
pragmatic trial is needed to confirm effectiveness when 
implemented as part of routine practice across a clinically 
relevant population with ARF.
Prior to a large pragmatic trial and economic eval-
uation, it is first necessary to estimate the incidence of 
eligible patients to determine whether a trial would be 
feasible and cost effective. It is also important to deter-
mine whether prehospital CPAP can be delivered success-
fully in the context of the NHS ambulance services. For 
these reasons, a stand- alone feasibility study is necessary 
to estimate the incidence of eligible patients, test the 
feasibility and acceptability of potential definitive trial 
methods, and address important uncertainties, such as 
patient selection, delivery of the intervention and event 
rates.
METHODS
Study design, aims and objectives
The Ambulance CPAP: Use, Treatment effect and 
Economics (ACUTE) study was an open- label, individual 
randomised, pragmatic, parallel group, external pilot 
trial. It aimed to determine the feasibility of a definitive 
trial evaluating the effect of prehospital CPAP (inter-
vention arm) compared with standard oxygen therapy 
(control arm) on 30- day mortality from ARF. The feasi-
bility and effectiveness outcomes are listed in table 1. A 
protocol, with preplanned outcomes and analysis plan, 
has been previously published.9 Health economic results 
will be reported separately.
Setting and study population
Recruitment took place across four hubs covering 
1.5 million people in an English ambulance service 
between 1 August 2017 and August 2018 (last follow- up 
completed 13 August 2018). Adults with respiratory 
distress and peripheral oxygen saturation below British 
Thoracic Society (BTS) target levels (88% for patients 
with COPD, 94% for other conditions) despite supple-
mental oxygen (titrated low flow oxygen for COPD, or 
titrated high flow oxygen in other conditions) were 
eligible.10 Patients with pre- existing lack of capacity; or 
with limited potential to benefit from, or contraindica-
tions to CPAP, were excluded. Inclusion and exclusion 
Table 1 Ambulance CPAP: Use, Treatment effect and Economics trial objectives and outcomes
Feasibility outcomes Feasibility targets
1.Rate of eligible patients per 100 000 population per year Target 8 per 100 000 per year, that is, 120 across the 
1.5 million population of the 4 hubs
2.Proportion recruited and allocated to treatment 
appropriately
Proportion recruited in error and classiied as major or minor 
non- compliances (target 0% and ≤10%).
3.Adherence to allocated treatment Adherence to the allocation schedule (target ≥90%)
Adherence to treatment in the CPAP arm (target ≥75%)
4.Retention and data completeness up to 30 days Retention at 30 days (target ≥90%)
Data completeness (target ≥90%)
Clinical outcome measures
1. Proportion surviving to 30 days (primary outcome for deinitive trial)
2. Proportion undergoing endotracheal intubation by 30 days
3. Proportion admitted to critical care at any point up to 30 days
4. Mean and median length of hospital stay
5. Change in Visual Analogue Scale dyspnoea score from presentation to immediately before ED arrival
6. Mean change in quality of life, measured with EQ- 5D- 5L
7. Key elements of postdischarge healthcare resource use up to 30 days
CPAP, continuous positive airway pressure ; EQ- 5D- 5L, EuroQOL- 5D- 5L Value Sets.
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criteria are detailed in box 1 and were based on clinician 
judgement at the scene of incident.
Randomisation
Enrolled patients were individually allocated to CPAP 
or standard oxygen therapy in a 1:1 ratio using simple 
randomisation. The randomisation sequence was 
computer generated by an independent statistician not 
directly involved in the conduct of the trial. The alloca-
tion schedule was held centrally on a password- protected, 
access- restricted network drive. The trial statistician did 
not have access to the randomisation sequence until after 
data lock.
Participant enrolment and consent
Ambulance service clinicians (paramedics and ambu-
lance technicians) volunteering to participate in the 
ACUTE study and trained in trial procedures identified 
potential participants with ARF when attending emer-
gency 999 ambulance calls. In patients judged to have 
capacity, verbal consent was obtained for participation. 
Eligible patients lacking mental capacity were enrolled 
in the trial without consent if determined to be in 
their best interests. In all cases, a research paramedic 
reviewed the participant in hospital as soon as possible 
after enrolment, obtaining consent for further data 
collection and participation in the trial according to the 
provisions of the Mental Capacity Act 2005.11 12 In the 
contingency that consent was declined, prehospital data 
were retained and anonymised 30- day mortality data 
collected. If a patient died before approach for written 
consent, ethical approval allowed for collection of 
anonymised prehospital, hospital and 30- day mortality 
data.
Allocation concealment and blinding
CPAP devices and high concentration oxygen therapy 
masks were packaged in identically appearing, numbered, 
shrink wrapped, tamper proof sealed, trial equipment 
boxes. Equipment boxes were independently assembled 
in an audited process in accordance with the randomisa-
tion sequence at Sheffield Clinical Trials Research Unit. 
Boxes were supplied to participating ambulance hubs, 
and held unordered by number, in a secure designated 
storage area. Boxes were subsequently signed in and out 
for each shift by participating clinicians. Research para-
medics audited the location and condition of all boxes, 
and adherence to the allocation schedule on a weekly 
basis. Due to the physical differences between the CPAP 
device and standard oxygen mask, it was not possible to 
subsequently blind patients, ambulance service clinicians, 
hospital clinicians or outcome assessors to the treatment 
arms.9
Trial treatments
Immediately after enrolment, paramedics opened the 
trial equipment box and provided treatment according 
to whether a CPAP device or high concentration oxygen 
mask was supplied. Patients in the intervention arm were 
treated with the O- Two unit (O- Two Medical Technolo-
gies, Ontario, Canada; supplied by SP Services (UK), 
Telford, UK), a lightweight, portable, open, single use, 
low flow CPAP system.7 CPAP was started at 5 cm H
2
O and 
then incrementally increased by 1 cm H
2
O every 2–5 min 
to a maximum of 15 cm H
2
O. Patients in the control arm 
received standard oxygen therapy using nasal cannula, an 
air entrainment Venturi mask, a simple face mask or a 
non- rebreathing reservoir face mask. The choice of flow 
rate and oxygen delivery device was titrated by ambulance 
service clinicians according to the patient’s condition, 
and peripheral oxygen saturation levels.
Treatment in both arms was targeted to BTS guide-
lines for peripheral oxygen saturations.8 Target periph-
eral oxygen saturations were 88%–92% for patients with 
known/suspected COPD and 94%–98% for patients 
with other suspected causes of ARF. Ancillary condition- 
specific treatments were administered in both trial arms 
according to Joint Royal Colleges Ambulance Liaison 
Committee Clinical Practice Guidelines.7 Subsequent 
hospital management, including emergency department 
CPAP or non- invasive ventilation (NIV), was at the discre-
tion of the hospital clinician.
Box 1 Ambulance CPAP: Use, Treatment effect and 
Economics (ACUTE) trial eligibility criteria
Inclusion criteria
All of:
 Ź Adults≥18 years
 Ź Respiratory distress
 Ź Hypoxiahypoxia:
 – Chronic obstructive pulmonary disease: Sats <88% despite low 
low oxygen
 – Other conditions: Sats <94% despite high low oxygen.
Exclusion criteria
Any of:
1. Hospital continuous positive airways pressure (CPAP) treatment 
available within 15 min of eligibility assessment
2. Age <18 years
3. Known to have terminal illness
4. Known pre- existing lack of capacity (conirmed by relatives, carers 
or documentary evidence, such as Lasting Power of Attorney)
5. Documented not for resuscitation status
6. Acutely incapacitated patients with known valid advanced directive 
declining non- invasive ventilation or participation in research
7. The patient has an oxygen alert card*
8. Anticipated inability to apply CPAP (eg, facial deformity)
9. Respiratory failure due to chest trauma
10. Contraindication to CPAP (suspected pneumothorax, respiratory 
arrest, epistaxis, vomiting, hypotension)
11. Previous enrolment in the ACUTE trial
12. Pregnancy
13. Patients unable to communicate with ambulance service clinicians
*Patient- held card warning against use of high low oxygen. Provided 
to patients with a history of previous hypercapnic acidosis with a 
PaO
2
 >10.0 kPa—indicating that oxygen may have worsened the 
hypercapnia.
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Data collection and safety reporting
Electronic patient records and computer- aided dispatch 
data were screened by research paramedics to identify 
potentially eligible, but unenrolled, patients. Routinely 
collected prehospital data (eg, timings, vital signs) were 
collated from participants’ electronic records by research 
paramedics. Additional trial specific information was 
collected using a trial form completed by recruiting ambu-
lance service clinicians and contained within each equip-
ment box. At 30 days, research paramedics reviewed the 
hospital records to collate details of subsequent progress, 
treatments and vital status at 30 days. Quality of life and 
postdischarge resource use was assessed by questionnaire 
at 30 days following enrolment, either in person if still in 
hospital, or by telephone or post if discharged. Adverse 
health changes in participants were defined, monitored, 
recorded and reported according to UK Health Research 
Authority guidance.13
Sample size and statistical analyses
The baseline characteristics of enrolled patients are 
reported descriptively for the whole trial population, 
and separately per treatment arm. Feasibility outcomes 
are reported descriptively for the whole trial population, 
together with their 95% CI. Summary estimates of rela-
tive and absolute effectiveness outcomes are presented, 
overall and stratified by treatment arm, with 95% CIs. 
An intention- to- treat analysis was used, using either a full 
analysis set, or a complete case analysis for endpoints with 
missing outcome data.14
The ACUTE feasibility study aimed to recruit 120 
patients over 12 months, the minimum number recom-
mended to estimate binary parameters for the sample 
size calculation of the full trial.15 Mortality under stan-
dard care was estimated at 12% and for the full trial a 
5% absolute reduction was postulated (ie, to 7%) in the 
intervention arm.1 3 4 This sample size would allow esti-
mation of mortality to within an SE of 2.7% for use in 
the sample size calculation for any definitive trial, and 
feasibility outcomes to be estimated with a precision of 
<5%. Achieving this target would also indicate a recruit-
ment rate sufficient to deliver the sample size for a defin-
itive trial, and an incidence of ARF necessary to deliver a 
potentially cost- effective prehospital CPAP service.
All analyses were conducted in the R statistical package 
(R Foundation for Statistical Computing, Vienna, Austria) 
in accordance with a prespecified statistical analysis plan 
and Consolidated Standards of Reporting Trials princi-
ples. Following review of blinded outcome data during 
trial management group (TMG) meetings, an unexpect-
edly high overall mortality rate was noted. A post- hoc 
descriptive analysis of the deceased patients was therefore 
conducted.
Public and patient involvement
The public and patients were fully involved in the ACUTE 
study from conception to dissemination. The research 
proposal was developed in partnership with a service user 
coapplicant and patient advisory groups. A service user 
advisory group was enlisted for collaboration throughout 
the project, and a lay coapplicant provided advice on 
trial matters, attended TMG meetings, supported study 
management and contributed to the study report and 
interpretation of result
RESULTS
Recruitment and consent
Over the recruitment period, 364 patients with ARF 
meeting ACUTE trial eligibility criteria presented from 
the 1.5 million population of four participating ambu-
lance service hubs. One hundred sixty- one of those 
patients (44.2%) were attended by ACUTE trained ambu-
lance service clinicians and could potentially have been 
recruited. Of these 161, 77 (47.8%) were enrolled in 
the trial. Slightly more participants were randomised to 
the CPAP intervention arm (42 cases), than to the stan-
dard oxygen control arm (35 cases). Consent for further 
data collection was declined by 9 patients (11.7%) and 
17 patients (22.1%) died prior to research paramedic 
approach for consent. Figure 1 presents the participant 
flow for the trial.
Baseline characteristics
The trial population was relatively elderly (median age 71 
years), predominantly male (62.3%) and severely unwell 
(median Visual Analogue Scale (VAS) breathlessness 
score 9/10, median pulse 115 beats/min, median respi-
ratory rate 34 breaths/min and median initial peripheral 
Figure 1 Consolidated Standards of Reporting Trials 
diagram of participants’ low through the Ambulance CPAP: 
Use, Treatment effect and Economics pilot trial. ARF, acute 
respiratory failure; CPAP, continuous positive airways 
pressure; DNAR, Do not attempt resuscitation.
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oxygen saturations of 78.5%). The most common final 
hospital diagnoses were COPD (n=21/65, 32.3%) and 
lower respiratory tract infection (n=28/65, 43.1%). A 
minority of cases (n=4/65, 6.2%) had a non- respiratory 
primary hospital diagnosis comprising abdominal aortic 
aneurysm, myocardial infarction, sepsis (not further spec-
ified) and liver failure (ascites). Prerandomisation char-
acteristics were similar across trial arms as summarised in 
table 2.
Feasibility outcomes
Feasibility outcomes, compared with the prespecified 
target, are summarised in table 3. The sample size of 
77 enrolled patients resulted in a recruitment rate of 
5.1 (95% CI 4.1 to 6.4) per 100 000 population per year, 
falling short of the feasibility target of 8 per 100 000 popu-
lation per year (ie, 120 patients).
All patients were recruited appropriately with no major 
or minor protocol non- compliances (targets of ≤10% and 
0%, respectively). There was full adherence to the allo-
cation schedule (feasibility target ≥90%). Treatment with 
CPAP was attempted in all patients enrolled in the inter-
vention arm. All patients received appropriate standard 
oxygen management in the control arm, although one 
patient was enrolled who used their own CPAP machine.
CPAP was fully delivered as planned (ie, administered 
until hospital arrival, or discontinued due to patient 
improvement after successful treatment) in 73.8% 
(31/42, target 75%) of intervention arm patients. CPAP 
Table 2 Baseline characteristics of Ambulance CPAP: Use, Treatment effect and Economics trial participants by arm
Baseline variable
Descriptive 
statistic
CPAP
N=42
Standard oxygen 
therapy
N=35
Total
N=77
Age Median (IQR) 70.0 (60.5 to 76.8) 73.0 (65.0 to 77.0) 71.0 (62.0 to 77.0)
Sex Male 27 (64.3%) 21 (60.0%) 48 (62.3%)
Hospital ARF diagnosis* n= 36 30 66
Asthma 1 (2.8%) 1 (2.9%) 2 (3.0%)
COPD 10 (27.8%) 11 (36.7%) 21 (31.8%)
Heart Failure 4 (11.1%) 2 (6.7%) 6 (9.1%)
LRTI 17 (47.2%) 11 (36.7%) 28 (42.4%)
Pulmonary 
embolism
1 (2.8%) 0 (0.0%) 1 (1.5%)
Other 3 (8.3%) 4 (13.3%) 7 (10.8%)
Breathlessness at enrolment
(VAS 0–10)
n= 41 35 76
Median (IQR) 9.0 (8.0 to 10.0) 9.0 (8.0 to 9.5) 9.0 (8.0 to 10.0)
First systolic blood pressure 
(mm Hg)
n= 40 30 70
Median (IQR) 136.0 (115.2 to 150.5) 126.5 (112.0 to 152.0) 134.5 (112.2 to 152.0)
First Glasgow Coma Score n= 42 35 77
Median (IQR) 15.0 (14.0 to 15.0) 15 (14.5 to 15.0) 15 (14.0 to 15.0)
First oxygen saturations (%) n= 41 35 76
Median (IQR) 78 (74.0 to 85.0) 82 (75.5 to 86.0) 78.5 (74.8 to 86.0)
First pulse rate (beats/min) n= 42 33 75
Median (IQR) 117.0 (105.0 to 125.8) 111 (92.0 to 121.0) 115 (100.0 to 124.0)
First respiratory rate (breaths/
min)
n= 42 35 77
Median (IQR) 36.0 (30.5 to 40.0) 32 (24.0 to 40.0) 34 (28.0 to 40.0)
Duration between arrival 
at scene and departure to 
hospital (min)
Median (IQR) 43.0 (34.0 to 49.8) 36.0 (32.5 to 46.5) 40.00 (34.0 to 49.0)
Duration between leaving the 
scene and arriving at hospital 
(min)
Median (IQR) 13.0 (9.00 to 18.75) 15.0 (10.0 to 20.5) 13.0 (10.0 to 20.0)
'N' refers to the total sample. 'n' refers to the subgroup numbers.
*Consent was declined for data collection in nine cases, clinical records were unavailable in two cases, and in one case there was no clear 
underlying diagnosis apparent in the notes.
ARF, acute respiratory failure; COPD, chronic obstructive pulmonary disease; LRTI, lower respiratory tract infection; VAS, Visual Analogue 
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was commenced in 90.5% of patients (38/42), with two 
patients refusing to wear the mask, one patient sponta-
neously improving and a fourth patient having a cardiac 
arrest prior to commencement. Of patients commencing 
CPAP, 31 (81.6%) continued with CPAP until they arrived 
at hospital: 6 did not tolerate CPAP and the remaining 
patient (with a final diagnosis of pulmonary fibrosis) was 
transferred to a standard oxygen non- rebreather mask 
due to non- improvement.
Full data were available for key outcomes, including all 
feasibility endpoints and vital status at 30 days, compared 
with the feasibility targets of ≥90% retention at 30 days 
and ≥90% data completeness. A small amount (<1%) 
of prehospital data describing baseline patient charac-
teristics was not available due to missing values. A larger 
proportion of hospital data was missing secondary to lack 
of consent for collection (n=9, 11.7%), absence of local 
research approvals to access hospital data (n=2, 2.6%), 
or unclear or absent information in the hospital clinical 
records (differing across variables, ranging from n=0, 0%, 
for hospital length of stay to n=25, 32.5%, for emergency 
department management). Of patients alive at 30 days 
(n=56), 30- day follow- up questionnaires examining 
quality of life and postdischarge health resource use were 
fully completed by 40 patients (71.4%).
Effectiveness and safety outcomes
Overall mortality of the study population was higher 
than expected with 27.3% (n=21/77) patients dying 
by 30 days. 28.6% (n=12/42) patients died by 30 days 
in the CPAP arm and 25.7% (n=9/35) in the standard 
oxygen arm (expected 12%). The absolute risk differ-
ence of mortality in CPAP group compared with standard 
oxygen therapy was 2.9% (95% CI −19.7% to 25.4%). An 
unplanned descriptive analysis of the deceased patients 
was undertaken to explore the circumstances for the 
unexpectedly high mortality rate. Data were not available 
for two cases due to lack of research approvals to access 
data, and two patients died from non- cardiorespiratory 
conditions not amenable to NIV (ruptured abdominal 
aneurysm and liver failure). Of the remaining 17 cases, 
6 patients (35.3%) received hospital NIV (n=5/17, 
Table 3 Summary of feasibility results
Feasibility outcome Target Result
Recruitment rate 8 per 100 000 population per year (ie, 120 
patients recruited)
 Ź 5.1 (95% CI 4.1 to 6.4) per 100 000 
population per year
 Ź 77 enrolled patients.
Major and minor non- compliances 0% and ≤10%  Ź 0%—major non- compliances
1.3%—minor non- compliance
Adherence to the allocation schedule Target ≥90%  Ź 100% adherence to allocation 
schedule
Adherence to treatment in the CPAP arm Target ≥75%  Ź 74%—CPAP fully delivered as 
planned
Retention at 30 days Target ≥90%  Ź 100%—follow- up for all feasibility 
endpoints and 30- day mortality
Data completeness Target ≥90% Data completeness for outcomes:
 Ź 100%—feasibility outcomes
 Ź 100%–30- day mortality
 Ź 81%–30- day intubation
 Ź 84%—admission to critical care
 Ź 99%—clinician assessed 
breathlessness
 Ź 86%—length of hospital stay
 Ź 85%—baseline EQ- 5D- 5L*
 Ź 71%–30- day EQ- 5D- 5L*
 Ź 73%–30- day resource use*
*Of alive patients.
CPAP, continuous positive airways pressure; EQ- 5D- 5L, EuroQOL- 5D- 5L Value Sets.
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29.4%) or mechanical ventilation (n=1, 5.9%). The other 
11 patients had hospital ceiling of treatment decisions 
excluding hospital NIV and critical care management 
(11/17, 64/7%). Other secondary effectiveness outcomes 
are summarised in table 4, and were similar across trial 
arms. Postdischarge resource use is summarised in online 
supplementary file 1.
In total, 39 expected related serious adverse events 
(SAE) occurred in 34 patients (45.2% for the CPAP 
arm, 42.9% for the standard oxygen therapy arm). The 
majority were deaths (20/39, 51.2%) or readmission to 
hospital within 30 days (13/39, 33.3%). There were no 
unexpected related SAEs. Two patients (one intervention 
arm patient not receiving CPAP and one control arm 
patient) were categorised with related expected SAEs 
following diagnosis with pneumothoraces requiring inter-
costal drainage after hospital admission. There were no 
significant SAEs attributable to CPAP therapy. Adverse 
events are detailed in online supplementary file 2.
DISCUSSION
Summary of results
Over 12 months, 77 patients were enrolled, below the 
recruitment target of 120 participants. CPAP was fully 
delivered as planned in 74% of intervention arm patients 
(target 75%). There were no major protocol violations. 
Full data were available for key outcomes, including all 
feasibility endpoints and vital status at 30 days. Mortality 
was higher than expected, with 27.3% of patients dying 
by 30 days. Of the deceased patients, 68% either did not 
have a respiratory condition or had explicit or implicit 
ceiling of treatment decisions excluding hospital NIV 
or critical care. Two patients, neither receiving CPAP, 
Table 4 Summary of effectiveness outcomes
Effectiveness outcome
CPAP
Standard oxygen 
therapy Total Absolute risk difference
N=42 N=35 N=77 (95% CI)
30- day mortality n=42 n=35 n=77
12 9 21 2.90%
−28.60% −25.70% −27.30% (−19.7 to 25.4)
Intubated n=33 n=29 n=62
2 1 3 2.60%
−6.10% −3.40% −4.80% (−10.5 to 15.7)
Admission to critical care n=35 n=30 n=65 4.80%
4 2 6 (−12.1 to 21.7)
−11.40% −6.50% −9.20%
Median of the difference 
(95% CI)
Median length of stay (days, IQR) n=22 n=22 n=44 3
10 7 8 (−0.00 to 6.00)
(6.5 to 12) (5 to 9.8) (5.5 to 11.2)
Change in patient reported 
breathlessness over prehospital 
interval (VAS, IQR)
n=18 n=18 n=36 −2
−3 −2 −2.5 (−3.00 to 0.00)
(−4 to –2) (−4 to –1) (−4 to –1)
Change in clinician assessed 
breathlessness over prehospital 
interval (VAS, IQR)
n=41 n=35 n=76 −1
−3 −2 −2 (−2 to 0)
(−5 to –1) (−3.5 to 1) (−4 to –1)
30- day EQ- 5D- 5L (IQR) n=22 n=18 n=40 0.08
0.82 0.73 0.76 (−0.6 to 0.26)
(0.58 to 0.95) (0.43 to 0.89) (0.48 to 0.92)
Median change in EQ- 5D- 5L (IQR) n=22 n=18 n=40 0.0 (−0.12 to 0.16)
0.09 0.1 0.09
(−0.01 to 0.16) (−0.06 to 0.19) (−0.02 to 0.18)
'N' refers to the total sample. 'n' refers to the subgroup numbers.
EQ- 5D- 5L, EuroQOL- 5D- 5L value sets; VAS, Visual Analogue Scale.
 o
n
 July 24, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-035915 on 23 July 2020. Downloaded from 
8 Fuller G, et al. BMJ Open 2020;10:e035915. doi:10.1136/bmjopen-2019-035915
Open access 
were diagnosed with a pneumothorax in the emergency 
department and were reported as expected related SAEs.
Interpretation
These findings suggest that pilot study methods could 
be used for a future definitive trial. Patients were appro-
priately recruited using a deferred consent model, there 
were no protocol violations, adherence to the allocation 
schedule was complete and full data were available for 
key outcomes. The ACUTE pilot trial demonstrated a 
recruitment rate that was below the target rate consid-
ered a priori necessary to deliver a definitive pragmatic 
trial. However, the majority of potentially eligible cases 
presented to non- trial trained staff and it is therefore 
possible that recruitment could be improved if a full 
trial mandated participation of all ambulance service 
personnel.
External pilot trials are not designed or powered to 
generate estimates of clinical effect that should be used 
for decision- making.16–18 We therefore draw no conclu-
sions from comparisons of outcomes between CPAP and 
standard care. However, a number of findings from the 
ACUTE pilot trial can be used to inform a judgement 
regarding whether it would be plausible for a large trial 
to detect an effect from CPAP on mortality and therefore 
whether a definitive trial might be worthwhile.
First, it is apparent that prehospital identification of 
patients with the potential to benefit from CPAP may be 
challenging. A small, but significant minority of cases were 
ultimately diagnosed with conditions where CPAP could 
not conceivably be beneficial.8 19 It is also concerning 
that pneumothoraces requiring intercostal drainage were 
detected in two cases. Although neither patient received 
prehospital CPAP, the potential for iatrogenic harm is 
conspicuous.
Second, delivery of CPAP was relatively limited, with 
74% of intervention arm patients continuing treatment 
to hospital as planned. Although CPAP may be effica-
cious, the potential to demonstrate effectiveness would 
be restricted by lack of treatment compliance.
Third, a key rationale for the implementation of 
prehospital CPAP is that earlier instigation of treatment 
will improve outcomes over and above the availability of 
hospital NIV.5 In the pilot trial, relatively short on- scene 
times and conveyance times were recorded (median of 
40 min and 13 min, respectively). The potential time 
advantage from prehospital administration of CPAP may 
be too small to produce meaningful benefit.
Finally, illness severity was much higher than antic-
ipated. The increased overall 30- day mortality risk of 
27.3% might initially appear to offer a definitive trial a 
greater opportunity to detect a clinically relevant survival 
benefit. However, many enrolled patients had apparent 
treatment limitation decisions for ward- level hospital care 
only, indicating a study population with a high prevalence 
of end- stage cardiorespiratory disease, multiple severe 
comorbidities or very poor premorbid performance 
status where CPAP treatment might be futile and overly 
burdensome. However, it should be noted that CPAP 
could also affect important patient- centred outcomes 
such as symptom relief, which might be detected by 
differences in dyspnoea VAS scores.
In summary, although the higher than expected 
mortality rate might suggest increased potential to detect 
an absolute difference in mortality, the challenges of 
providing prehospital CPAP, and characteristics of the 
patients who would benefit from CPAP, suggest limited 
potential to improve survival. It therefore appears unlikely 
that a trial powered to detect a plausible effect size could 
be designed.
Limitations
The purpose of a feasibility study is to determine if a large- 
scale trial can be performed.18 Therefore, challenges that 
might be interpreted as weaknesses when appraising 
a definitive RCT (such as low rates of recruitment and 
adherence) actually represent important learning points 
in the feasibility setting. Modification of eligibility criteria 
to specify the presence of a primary cardiorespira-
tory diagnosis as an inclusion criteria, and exclusion of 
patients with home CPAP machines, could select a more 
appropriate study population. The use of retrospective 
case note review for hospital data collection improved the 
efficiency of data collection, but is associated with well- 
recognised limitations that could have resulted in inac-
curate measurement of study endpoints. Furthermore, 
collection of more detailed data on NIV treatment in the 
emergency department would be beneficial in any future 
trial.
Generalisability
Trial eligibility criteria were broad, excluding only 
patients where CPAP was contraindicated (eg, vomiting), 
where entry would likely not be appropriate (eg, do not 
resuscitate status, pre- existing loss of capacity), or where 
verbal consent was not possible (eg, language barrier). 
The clinical findings reported herein should therefore 
have strong generalisability to patients presenting with 
ARF in NHS ambulance services. External validity to 
other settings, with different demographics or prehospital 
systems, is less clear. For example, international emer-
gency medical services may have shorter on- scene times, 
use CPAP in less severe ARF, or use prehospital physicians 
with ultrasound skills to detect pneumothorax before 
CPAP application. Furthermore, a novel CPAP device 
was used. Although there are considerable advantages 
to the studied O- Two unit including small size, low cost 
and simplicity, there may also be limitations compared 
with other more complex prehospital CPAP systems, for 
example, FiO
2
 and CPAP level are jointly determined by 
the oxygen flow rate. Consequently, efficacy could differ 
with other methods of delivering prehospital CPAP.
Comparison to previous literature
A series of recent observational studies have also demon-
strated that CPAP can be implemented by Emergency 
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Medical Services (EMS).20–24 These studies are consis-
tent with the ACUTE experience of submaximal CPAP 
adherence and difficult prehospital diagnosis, including 
treatment of patients with pneumothoraces. A recent 
systematic review identified 10 trials and quasi- randomised 
studies comparing prehospital NIV (including CPAP) 
with standard oxygen therapy.5 Network meta- analysis 
suggested that prehospital CPAP is an effective treatment 
for ARF, with evidence that it reduces mortality (OR 0.41; 
95% CrI 0.20 to 0.77) and intubation rate (0.32; 95% CrI 
0.17 to 0.62) compared with standard care.2 However, 
some included studies were at risk of selection bias from 
lack of allocation concealment and information bias, 
secondary to unblinded outcome assessment. Further-
more, the meta- analysis findings have doubtful external 
validity to prehospital practice in many settings. Only one 
trial included patients with undifferentiated respiratory 
failure, and the methods used to deliver prehospital CPAP 
(physician or paramedics with online physician support) 
are not routine in many prehospital care systems, reflected 
in higher levels of CPAP compliance.5
CONCLUSIONS
Pilot trial recruitment rate was below the target rate. 
Limited compliance with CPAP, and a study population 
including patients who could not benefit from CPAP, 
suggest that a clinically significant effect size is not plau-
sible. A definitive effectiveness trial of CPAP is therefore 
not recommended. These findings also argue against 
routine implementation of CPAP into many ambulance 
services, but would not preclude a CPAP service provided 
by clinicians with extended training (eg, prehospital physi-
cians) where advanced clinical skills might allow selective 
targeting of treatment to an appropriate subgroup of 
patients.
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